Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$10.04 USD

10.04
734,781

+0.07 (0.70%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add ResMed (RMD) in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.

Bio-Rad Rides on International Expansion Amid Cost Concerns

by Zacks Equity Research

Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.

Bio-Rad Launches Serology Test to Detect Coronavirus Antibody

by Zacks Equity Research

Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.

Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View

by Zacks Equity Research

Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.

Integra Releases Preliminary Q1 Results, Withdraws '20 View

by Zacks Equity Research

Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.

Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns

by Zacks Equity Research

Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.

Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement

by Zacks Equity Research

Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.

Product Launches Aid Hill-Rom Amid Project Timing Issues

by Zacks Equity Research

Hill-Rom (HRC) plans to roll out five-six new products each year through 2022.

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.

Haemonetics (HAE) Buys enicor to Expand Testing Portfolio

by Zacks Equity Research

Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.

Align Technology Buys exocad to Expand Its Digital Platform

by Zacks Equity Research

Align Technology (ALGN) expands its portfolio with the buyout completion of exocad. This will help the company offer fully integrated workflows to dental labs and dental practices worldwide.

IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches

by Zacks Equity Research

Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.

Here's Why You Should Hold on to Teleflex (TFX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international growth in the fourth quarter of 2019.

Why Is National Vision (EYE) Down 37% Since Last Earnings Report?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

National Vision (EYE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

National Vision Grows on Positive Comps, Rising Costs a Woe

by Zacks Equity Research

National Vision's (EYE) positive comparable store sales (comps) growth story continues for 72 consecutive quarters.

National Vision (EYE) Rides on Robust Growth Across All Lines

by Zacks Equity Research

National Vision (EYE) continues to register strong segmental performances.

Teleflex Hits New 52-Week High: What's Driving the Rally?

by Zacks Equity Research

Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.

Thermo Fisher Rides on New Product Suite, Currency Woes Stay

by Zacks Equity Research

Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.

Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod

by Zacks Equity Research

Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

by Zacks Equity Research

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

Here's Why You Should Add NuVasive Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.

Edwards (EW) Rides on Innovation Despite Regulatory Issues

by Zacks Equity Research

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

by Zacks Equity Research

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.